Assessment of celecoxib, a selective cox-2 inhibitor, as a neuroprotective agent in alzheimer’s model of rats

Reduced cerebral blood flow (CBF) has been associated with neurodegenerative disorders including Alzheimer’s disease. Experimentally, a condition of chronic cerebral hypoperfusion due to reduced CBF can be induced by permanent bilateral occlusion of common carotid arteries (2-vessel occlusion, 2VO)...

Full description

Bibliographic Details
Main Authors: Saxena, Anil Kumar, Noor, Mohd. Fadly, Talib, Norlelawati A.
Format: Proceeding Paper
Language:English
English
Published: 2013
Subjects:
Online Access:http://irep.iium.edu.my/29891/1/IRIIE_POSTER_2.pdf
http://irep.iium.edu.my/29891/4/Assessment_of_celecoxib%2C_a_selective_cox-2_inhibitor%2C_as_a_neuroprotective_agent_in_alzheimer%E2%80%99s_model_of_rats.pdf
_version_ 1825647264967688192
author Saxena, Anil Kumar
Noor, Mohd. Fadly
Talib, Norlelawati A.
author_facet Saxena, Anil Kumar
Noor, Mohd. Fadly
Talib, Norlelawati A.
author_sort Saxena, Anil Kumar
collection IIUM
description Reduced cerebral blood flow (CBF) has been associated with neurodegenerative disorders including Alzheimer’s disease. Experimentally, a condition of chronic cerebral hypoperfusion due to reduced CBF can be induced by permanent bilateral occlusion of common carotid arteries (2-vessel occlusion, 2VO) in rats. Neuroinflammation has been suggested to plays a crucial role in the development and progression of many neurodegeneative diseases. The neuroinflammatory response induces activation of microglia and release of inflammatory mediators such as prostaglandins, leukotrienes, and cytokines. The sustained release of inflammatory mediators works to perpetuate the inflammatory cycle and leads to apoptosis and neuronal cell death. Since neuroinflammation, leading to neuronal apoptosis and death, is one of the mechanisms which is thought to play a significant role in chronic degenerative neurological disorders like Alzheimer’s disease, the present study was planned to assess the neuroprotective role of celecoxib, a selective COX-2 inhibitor, in Alzheimer’s model of rats (2VO). After one week of acclimatization, fifteen Sprague Dawley rats weighing 200-250 g were equally divided into three groups. Group A served as – sham control, Group B – 2VO, and Group C – 2VO-C (treated daily with celecoxib 50 mg/kg, orally following 2VO). On 8th week, all the rats were euthanized and the hippocampi were isolated. Viable neuronal cells in the hippocampal CA-1 region were counted and hippocampal COX-2 mRNA expression and prostaglandin E2 (PGE-2) levels were estimated. There was a significant difference in neuronal cell death, increase in COX-2 mRNA expression and PGE-2 levels in 2VO group as compared to sham control group. In celecoxib-treated 2VO (2VO-C) rats, the viable neuronal cell count of the hippocampal CA-1 region was significantly higher as compared to the untreated 2VO group. The hippocampal COX-2 mRNA expression and hippocampal PGE-2 levels were found to be significantly lower in the celecoxib-treated 2VO rats as compared to untreated 2VO rats. The results clearly point out that celecoxib is an effective neuroprotective agent in Alzheimer’s model of rats and can be successfully used in the management of Alzheimer’s disease.
first_indexed 2024-03-05T23:15:05Z
format Proceeding Paper
id oai:generic.eprints.org:29891
institution International Islamic University Malaysia
language English
English
last_indexed 2024-03-05T23:15:05Z
publishDate 2013
record_format dspace
spelling oai:generic.eprints.org:298912013-08-16T09:19:05Z http://irep.iium.edu.my/29891/ Assessment of celecoxib, a selective cox-2 inhibitor, as a neuroprotective agent in alzheimer’s model of rats Saxena, Anil Kumar Noor, Mohd. Fadly Talib, Norlelawati A. RM300 Drugs and their action Reduced cerebral blood flow (CBF) has been associated with neurodegenerative disorders including Alzheimer’s disease. Experimentally, a condition of chronic cerebral hypoperfusion due to reduced CBF can be induced by permanent bilateral occlusion of common carotid arteries (2-vessel occlusion, 2VO) in rats. Neuroinflammation has been suggested to plays a crucial role in the development and progression of many neurodegeneative diseases. The neuroinflammatory response induces activation of microglia and release of inflammatory mediators such as prostaglandins, leukotrienes, and cytokines. The sustained release of inflammatory mediators works to perpetuate the inflammatory cycle and leads to apoptosis and neuronal cell death. Since neuroinflammation, leading to neuronal apoptosis and death, is one of the mechanisms which is thought to play a significant role in chronic degenerative neurological disorders like Alzheimer’s disease, the present study was planned to assess the neuroprotective role of celecoxib, a selective COX-2 inhibitor, in Alzheimer’s model of rats (2VO). After one week of acclimatization, fifteen Sprague Dawley rats weighing 200-250 g were equally divided into three groups. Group A served as – sham control, Group B – 2VO, and Group C – 2VO-C (treated daily with celecoxib 50 mg/kg, orally following 2VO). On 8th week, all the rats were euthanized and the hippocampi were isolated. Viable neuronal cells in the hippocampal CA-1 region were counted and hippocampal COX-2 mRNA expression and prostaglandin E2 (PGE-2) levels were estimated. There was a significant difference in neuronal cell death, increase in COX-2 mRNA expression and PGE-2 levels in 2VO group as compared to sham control group. In celecoxib-treated 2VO (2VO-C) rats, the viable neuronal cell count of the hippocampal CA-1 region was significantly higher as compared to the untreated 2VO group. The hippocampal COX-2 mRNA expression and hippocampal PGE-2 levels were found to be significantly lower in the celecoxib-treated 2VO rats as compared to untreated 2VO rats. The results clearly point out that celecoxib is an effective neuroprotective agent in Alzheimer’s model of rats and can be successfully used in the management of Alzheimer’s disease. 2013-02-19 Proceeding Paper PeerReviewed application/pdf en http://irep.iium.edu.my/29891/1/IRIIE_POSTER_2.pdf application/pdf en http://irep.iium.edu.my/29891/4/Assessment_of_celecoxib%2C_a_selective_cox-2_inhibitor%2C_as_a_neuroprotective_agent_in_alzheimer%E2%80%99s_model_of_rats.pdf Saxena, Anil Kumar and Noor, Mohd. Fadly and Talib, Norlelawati A. (2013) Assessment of celecoxib, a selective cox-2 inhibitor, as a neuroprotective agent in alzheimer’s model of rats. In: IIUM Research, Invention and Innovation Exhibition (IRIIE) 2013, 19-20 Feb 2013, Cultural Activity Centre (CAC) and KAED Gallery, IIUM. http://www.iium.edu.my/irie/13/index.php/8-iriie/1-iium-research-invention-and-innovation-exhibition-2013
spellingShingle RM300 Drugs and their action
Saxena, Anil Kumar
Noor, Mohd. Fadly
Talib, Norlelawati A.
Assessment of celecoxib, a selective cox-2 inhibitor, as a neuroprotective agent in alzheimer’s model of rats
title Assessment of celecoxib, a selective cox-2 inhibitor, as a neuroprotective agent in alzheimer’s model of rats
title_full Assessment of celecoxib, a selective cox-2 inhibitor, as a neuroprotective agent in alzheimer’s model of rats
title_fullStr Assessment of celecoxib, a selective cox-2 inhibitor, as a neuroprotective agent in alzheimer’s model of rats
title_full_unstemmed Assessment of celecoxib, a selective cox-2 inhibitor, as a neuroprotective agent in alzheimer’s model of rats
title_short Assessment of celecoxib, a selective cox-2 inhibitor, as a neuroprotective agent in alzheimer’s model of rats
title_sort assessment of celecoxib a selective cox 2 inhibitor as a neuroprotective agent in alzheimer s model of rats
topic RM300 Drugs and their action
url http://irep.iium.edu.my/29891/1/IRIIE_POSTER_2.pdf
http://irep.iium.edu.my/29891/4/Assessment_of_celecoxib%2C_a_selective_cox-2_inhibitor%2C_as_a_neuroprotective_agent_in_alzheimer%E2%80%99s_model_of_rats.pdf
work_keys_str_mv AT saxenaanilkumar assessmentofcelecoxibaselectivecox2inhibitorasaneuroprotectiveagentinalzheimersmodelofrats
AT noormohdfadly assessmentofcelecoxibaselectivecox2inhibitorasaneuroprotectiveagentinalzheimersmodelofrats
AT talibnorlelawatia assessmentofcelecoxibaselectivecox2inhibitorasaneuroprotectiveagentinalzheimersmodelofrats